The Fat Burn Phase 1 study, which is expected to last for at least a year, is about to be completed, a Mayo Clinic official told reporters.
The Mayo Clinic and the University of Minnesota are both collaborating on the study.
It will determine whether a fat loss regimen can be maintained without a decrease in the percentage of body fat and whether it is more effective than the standard regimen.
In July, Mayo reported that the Phase 1 trial, which has seen some success, found that the standard Fat Loss Spray regimen was about 10 percent effective.
The trial also showed that a low-fat diet was about 15 percent effective, and a moderate-fat one was about 23 percent effective at preventing weight loss.
The new phase 2 study will determine if the new regimen works more effectively and whether other types of fat loss can be achieved with a low fat diet, a low carb diet, or no diet at all.
The study will be published in the Journal of the American College of Cardiology, which will also publish the results.
In a statement to reporters, Mayo said it has not yet finalized the data it will use to determine which regimen is more efficacious and which type of fat reduction is more beneficial.
In the Phase 2 study, participants will follow either a lowfat or a lowcarb diet.
Low-fat participants will take part in an 18-week trial, while low-carb participants will do the same.
The Phase 2 trial is designed to last two years, and participants will be able to start their diet plan again in 2019.
The results of the Phase 3 study will likely be published as early as next year.
The Mayo Clinic said it will start sending out surveys to people who are enrolled in the trial in 2019, and will then send those surveys to a panel of experts in clinical medicine.
The phase 3 study is the largest of its kind.
The first two phases of the trial, the Phase I study and the Phase II study, saw similar results.
The results of Phase 1 and Phase II were generally similar, although some participants were randomized to a different diet, and some were randomized at random.
In June, Mayo announced that the first phase of the study, called the Phase III trial, had been completed.
This phase will have more participants, and Mayo said that it is also expected to have a higher proportion of participants who will be overweight or obese.
In addition, the Mayo Clinic will send out a questionnaire that will include information about how people responded to the trials, and the results of all the randomized studies so far.
In June, the researchers also said that they were going to test the efficacy of the new Phase 3 regimen, called Phase IV, on a large group of people.
The Phase III study will focus on people over age 50 and women over age 60.
In May, the study’s co-lead, a researcher at the Mayo Clinical and Translational Science Institute, Dr. Stephen O’Donnell, said that the results from the Phase IV study should be released next week.
In May, Mayo also announced that it will send a survey to a random sample of its own population.
The study is expected in 2019 or 2020.